scieee Open visual document viewer

Targeting Neuroblastoma Cell Surface Proteins: Recommendations for Homology Modeling of hNET, ALK, and TrkB

Haddad, Yazan Abdulmajeed Eyadh; Heger, Zbyněk; Adam, Vojtěch

Abstract

Targeted therapy is a promising approach for treatment of neuroblastoma as evident from the large number of targeting agents employed in clinical practice today. In the absence of known crystal structures, researchers rely on homology modeling to construct template-based theoretical structures for drug design and testing. Here, we discuss three candidate cell surface proteins that are suitable for homology modeling: human norepinephrine transporter (hNET), anaplastic lymphoma kinase (ALK), and neurotrophic tyrosine kinase receptor 2 (NTRK2 or TrkB). When choosing templates, both sequence identity and structure quality are important for homology modeling and pose the first of many challenges in the modeling process. Homology modeling of hNET can be improved using template models of dopamine and serotonin transporters instead of the leucine transporter (LeuT). The extracellular domains of ALK and TrkB are yet to be exploited by homology modeling. There are several idiosyncrasies that require direct attention throughout the process of model construction, evaluation and refinement. Shifts/gaps in the alignment between the template and target, backbone outliers and side-chain rotamer outliers are among the main sources of physical errors in the structures. Low-conserved regions can be refined with loop modeling method. Residue hydrophobicity, accessibility to bound metals or glycosylation can aid in model refinement. We recommend resolving these idiosyncrasies as part of “good modeling practice” to obtain highest quality model. Decreasing physical errors in protein structures plays major role in the development of targeting agents and understanding of chemical interactions at the molecular level.

Full text

PERSPECTIVE published: 20 Janua y 2017 doi: 10.3389/ nmol.2017.00007 Ta ge ing Neu oblas oma Cell Su ace P o eins: Recommenda ions o Homology Modeling o hNET, ALK, and T kB Yazan Haddad1,2,Zbynˇek Hege 1,2 and Voj ech Adam1,2* 1Depa men o Chemis y and Biochemis y, Mendel Uni e si y in B no, B no, Czechia, 2Cen al Eu opean Ins i u e o Technology, B no Uni e si y o Technology, B no, Czechia Edi ed by: De le Boison, Legacy Heal h, USA Re iewed by: Hong Qing, Beijing Ins i u e o Technology, China Nikki Ka he ine Ly le, Uni e si y o Cali o nia, San Diego, USA Da ide Comole i, Ru ge s Uni e si y, USA *Co espondence: Voj ech Adam [email p o ec ed] Recei ed: 26 Sep embe 2016 Accep ed: 06 Janua y 2017 Published: 20 Janua y 2017 Ci a ion: Haddad Y, Hege Z and Adam V (2017) Ta ge ing Neu oblas oma Cell Su ace P o eins: Recommenda ions o Homology Modeling o hNET, ALK, and T kB. F on . Mol. Neu osci. 10:7. doi: 10.3389/ nmol.2017.00007 Ta ge ed he apy is a p omising app oach o ea men o neu oblas oma as e iden om he la ge numbe o a ge ing agen s employed in clinical p ac ice oday. In he absence o known c ys al s uc u es, esea che s ely on homology modeling o cons uc empla e-based heo e ical s uc u es o d ug design and es ing. He e, we discuss h ee candida e cell su ace p o eins ha a e sui able o homology modeling: human no epineph ine anspo e (hNET), anaplas ic lymphoma kinase (ALK), and neu o ophic y osine kinase ecep o 2 (NTRK2 o T kB). When choosing empla es, bo h sequence iden i y and s uc u e quali y a e impo an o homology modeling and pose he i s o many challenges in he modeling p ocess. Homology modeling o hNET can be imp o ed using empla e models o dopamine and se o onin anspo e s ins ead o he leucine anspo e (LeuT). The ex acellula domains o ALK and T kB a e ye o be exploi ed by homology modeling. The e a e se e al idiosync asies ha equi e di ec a en ion h oughou he p ocess o model cons uc ion, e alua ion and e inemen . Shi s/gaps in he alignmen be ween he empla e and a ge , backbone ou lie s and side-chain o ame ou lie s a e among he main sou ces o physical e o s in he s uc u es. Low-conse ed egions can be e ined wi h loop modeling me hod. Residue hyd ophobici y, accessibili y o bound me als o glycosyla ion can aid in model e inemen . We ecommend esol ing hese idiosync asies as pa o “good modeling p ac ice” o ob ain highes quali y model. Dec easing physical e o s in p o ein s uc u es plays majo ole in he de elopmen o a ge ing agen s and unde s anding o chemical in e ac ions a he molecula le el. Keywo ds: neu oblas oma, a ge ed he apy, homology modeling, no epineph ine anspo e , anaplas ic lymphoma kinase, neu o ophic y osine kinase ecep o INTRODUCTION The la ge numbe o expe imen ally de e mined and deposi ed p o ein s uc u es in he da abases is a aluable sou ce o explo e uncha ed e i o ies o o he p o eins, which ha e simila sequence. Homology modeling, also known as compa a i e modeling, is used o cons uc ing p o ein models based on empla e s uc u es o homolog p o eins. In his pe spec i e a icle, we ha e highligh ed he main s uc u al issues in homology modeling o h ee candida e cell su ace p o eins o F on ie s in Molecula Neu oscience | www. on ie sin.o g 1Janua y 2017 | Volume 10 | A icle 7 Haddad e al. Homology Modeling o Ta ge ing Neu oblas oma neu oblas oma a ge ed he apy. In he nex sec ion, we emphasize he challenges aced in each s ep in he homology modeling p ocess. A b ie sec ion on a ge ing neu oblas oma desc ibes he ole o cell su ace p o ein a ge s in de eloping he apeu ics. A de ailed e alua ion o homology models expands on h ee chosen cell su ace p o ein candida es: human no epineph ine anspo e (hNET), anaplas ic lymphoma kinase (ALK), and neu o ophic y osine kinase ecep o ype 2 (NTRK2, commonly known as T kB). While he echnical aspec s o his manusc ip a o an audience o specialis s wo king on d ug disco e y and homology modeling o hese h ee a ge s, he same p inciples o model e alua ion and challenging issues can be applied o o he homology models. HOMOLOGY MODELING P o ein s uc u es a e he inal on ie s in unde s anding he human biology a he molecula le el. Gold s anda ds o c ys al s uc u e cha ac e iza ion a a omic esolu ion, such as X- ay c ys allog aphy and nuclea magne ic esonance (NMR) spec oscopy, can be now sa is ac o ily complemen ed wi h compu a ional me hods (Kund o as e al., 2012). Homology modeling is a sys ema ic compu a ional p ocess whe e he mos simila p o ein sequence, o a known c ys al s uc u e, is used o cons uc ion o a new model by eplacing he equi alen amino acids on an equi alen backbone. K iege e al. (2003) desc ibed se en s eps in homology modeling: (1) The choice o empla e(s) and ini ial alignmen a e he i s challenges in homology modeling. The accu acy o a homology model is co ela ed wi h he numbe o ma ching esidues in alignmen . A minimum 25% sequence iden i y has been he s anda d o homology modeling so a . Below 25% iden i y i is ecommended o use mul iple empla es o modeling. The quali y o empla e s uc u e is di ec ly inhe i ed in he homology model. Polishing o empla e s uc u e is a good p ac ice be o e use. Missing a oms should be ixed using o ame lib a y and he hanging e mini can be immed. (2) Alignmen co ec ion educes e o s caused by alse sequence iden i ies. Mul iple alignmen s and s uc u al alignmen s (e.g., posi ion-speci ic sco ing ma ices) a e ecommended al e na i es o con en ional alignmen s. This s ep is he mos c i ical in homology modeling be o e (3) backbone gene a ion, as i de e mines he o sional angles o he backbone in he model. I has been shown ha p oblems in he backbone can d as ically al e he co ec olding o he side-chains as well (Al-Lazikani e al., 2001). Issues ega ding empla e ecogni ion and alignmen will be highligh ed he e. F om ou expe ience, many o he spo adic e o s in modeling backbones a ise in p oline o adjacen o p oline esidues. (4) Loop modeling is impo an o co ec ing he olding o low-conse ed egions (i.e., loops) o p o ein. I is now possible o make accu a e models using da abase sea ch o ab ini io me hods o up o 8–13 esidues long loops (To o , 2012). Loop modeling employs po en ial ene gy sco es o e alua ion o he quali y o cons uc ed loop(s). I is also possible o use al e na i e a ionales o e alua ion based on biological unc ions. We show he e some examples o biological unc ions ha can include, exclude o guide he modeling p ocess such as hyd ophobici y, accessibili y o loop esidues o glycosyla ion o o binding o ions. (5) Side-chain modeling is di ec ly a ec ed by empla e sequence iden i y, alignmen and backbone. Iden ical esidues in wo homolog p o eins ha e nea ly iden ical o ame s. The SWISS-MODEL se e (Bo doli e al., 2009) and Modelle (Webb and Sali, 2014) a e among he mos commonly used pla o ms o backbone/side-chain homology modeling. Homology models a e subjec ed o inal op imiza ion and alida ion be o e conduc ing a ious kinds o compu a ional s udies such as ene ge ics (molecula mechanics), p o ein-d ug/p o ein-p o ein in e ac ions (molecula docking and p o ein ne wo ks), mu a ional analysis, and simula ion in physiological en i onmen (molecula dynamics). (6) Model op imiza ion, also known as ene gy minimiza ion, is applica ion o ene gy unc ions o compu e a global minimum ha ep esen s he mos na i e olding (Bo dne , 2012). Minimiza ion aims o adjus he geome ies o p o ein s uc u es o he ‘‘ o ce ield’’ pa ame e s used in compu a ional s udies. This me hod some imes e e ed o as ‘‘ elaxing he s uc u e’’ is su icien o esol e a omic clashes in he model. Howe e , he s o y is no inished he e. Se e al physical and s uc u al e o s should be esol ed. (7) Valida ion o he inal model(s) checks i he model complies wi h s anda d pa ame e s o p o ein s uc u e. These pa ame e s include: bond leng hs, bond angles, o sions, backbone ou lie s, o ame ou lie s and all a omic con ac s (Chen e al., 2010). E alua ion p ocedu e includes physics-based, knowledge-based and expe imen al-based me hods (Haddad e al., 2016). The same igo ous ules o e alua ion ha a e applied in c ys allog aphy mus also be applied in homology modeling. TARGETING NEUROBLASTOMA Neu oblas omas a e one o he mos common and a al solid umo s in child en below 2 yea s o age. Whe eas he su i al a es o mos ypes o cance in child en ha e imp o ed in he pas ew decades, neu oblas oma is s ill below 75% 5-yea su i al (Siegel e al., 2016). Ta ge ed he apy is a p omising app oach o de eloping ea men s o neu oblas oma. Ma hay e al. (2012) desc ibed h ee success ul he apeu ic a ge s o neu oblas oma ha a e in p ac ice oday: (1) hNET a ge ed by adio he apy ia 131I-me aiodobenzylguanidine (MIBG) (2) he GD2 ganglioside a ge ed by monoclonal an ibodies, and (3) ALK a ge ed by kinase inhibi o s. An ex ended lis o a ge s was p e iously compiled by Ve issimo e al. (2011), including hose in clinical ials. The as majo i y o FDA-app o ed medicines, pa icula ly hose disco e ed by a ional d ug design on molecula a ge s, wo k by pe u bing he unc ion o a ge s o p e en o e e se symp oms/disease (Kinch e al., 2015). I is impo an o dis inguish he e m a ge ed he apy, which occasionally indica es pe u bing he molecula a ge , om he gene al concep o a ge ing which also includes d ug deli e y by ecognizing cance cells. Hence, a ge ing also desc ibes he apeu ics able o deli e and elease ca go o he umo mic oen i onmen by binding o a ge s on he cance cell su ace (Shin e al., 2014). Such he apeu ics (e.g., pep ides and an ibodies) a e cha ac e ized by hei selec i i y o a ge s. They F on ie s in Molecula Neu oscience | www. on ie sin.o g 2Janua y 2017 | Volume 10 | A icle 7 Haddad e al. Homology Modeling o Ta ge ing Neu oblas oma can be de eloped ei he blindly ia sc eening me hods o by molecula modeling. The ideal a ge should be ‘‘abundan and accessible and should be exp essed homogeneously, consis en ly and exclusi ely on he su ace o cance cells’’ (Sco e al., 2012). Homology modeling has been success ully used in s uc u e- based design o many he apeu ics a ge ing di e en ypes o diseases including cance (Bu le e al., 2010; Schlessinge e al., 2011; DeVo e and Sco , 2012). Howe e , i is wo h men ioning wo ca ego ies o excellen p o ein a ge s in neu oblas oma ha a e beyond he scope o homology modeling: i s , p o eins which ha e known c ys al s uc u es such as CD147, which is associa ed wi h dec eased neu oblas oma di e en ia ion (Ga cia e al., 2009; W igh e al., 2014), and CD57, which has also been implica ed in agg ession o neu oblas oma (Kakuda e al., 2004; Schli e e al., 2012). Second, hose candida e a ge s which lack any empla e s uc u e. One o hese cases is a glycop o ein called CD133, and i s exp ession is associa ed wi h poo p ognosis o neu oblas oma (Sa ele e al., 2012). In compa a i e modeling o de elopmen o d ugs, he lesson lea ned is ha simila s uc u es o en exhibi simila unc ions. This is p oblema ic pa icula ly when d ugs a ge he p o ein and i s homologs simul aneously, esul ing in a ious side e ec s. The h ee a ge s hNET, ALK and T kB a e good examples o c oss in e ac ions esul ing in side e ec s. While hNET neu o ansmi e anspo o e laps wi h o he monoamine anspo e s, he kinase inhibi o s o ALK and T kB can a ge hei homologs, espec i ely. Bo h homology modeling and de elopmen o selec i e d ugs should ocus on he low-conse ed egions o a ge ed p o eins. hNET The hNET egula es he up ake and ecycle o no epineph ine in he neu ons. hNET is one o he highly exp essed p o eins in neu oblas oma (∼90% o cases) and mos commonly used in MIBG-based diagnosis/ he apy (B odeu e al., 1993; Ma hay e al., 2012) and de elopmen o new he apeu ics (Mo ensen and Ko age e, 2015). hNET p o ein has h ee iso o ms. The canonical iso o m is 617 esidues in leng h ye i is second o he longes iso o m which is 628 in leng h and di e s in he C- e minus. P e ious homology models o hNET elied on he c ys al s uc u e o p oka yo ic leucine anspo e (LeuT; Yamashi a e al., 2005) and d osophila dopamine anspo e (dDAT) c ys al s uc u es as empla es (Penma sa e al., 2013; Wang e al., 2015;Table 1). Two ecen ly published mu an se o onin anspo e (SERT) c ys al s uc u es (Coleman e al., 2016) designa ed s2 and s3 can also aid in homology modeling o hNET. The homology models cons uc ed by Schlessinge e al. (2011) and Koldsø e al. (2013) we e based on LeuT empla e. In ligh o newly published dDAT and SERT c ys al s uc u es, we ha e ecen ly add essed he de elopmen s ega ding homology modeling o hNET based on hese new empla es (Haddad e al., 2016). B ie ly, he e a e ou majo alignmen gaps cha ac e izing he sequences o dDAT, hNET and SERT; including he glycosyla ed ex acellula loop 2 (EL2), ex acellula loop 4 (EL4) and wo in acellula loops (Figu e 1A). Loop modeling is mos ly equi ed a he EL2 loop; pa icula ly esidues 189–207. A e cons uc ion o a numbe o loops, one should exclude hose wi h non-embedded leucines/ aline esidues due o hei hyd ophobici y. A i s glance, he accessibili y o he glycosyla ed esidues can be an indica o o non-embedded esidues in he loop (i.e., aspa agines). A leas wo glycosyla ed o ms o hNET a e known wi h molecula weigh s o 80 kD and 54 kD co esponding o a co e 46k D hNET p o ein (Melikian e al., 1994). I is nei he clea whe he all h ee aspa agines a e accessible o glycosyla ion no i indeed he e is a single con o ma ion o his loop. Mu an hNET (K189H) exhibi s a zinc binding si e in he EL2 loop (No egaa d e al., 1998), which migh sugges di ec p oximi y and accessibili y be ween K189 and nea es his idine H372. Howe e , no in o ma ion is a ailable on he p oximi y o H199 in he EL2 o hese esidues. Simila ly, se e al sodium and chlo ide ion binding si es a e epo ed in LeuT, dDAT and human SERT (hSERT; Yamashi a e al., 2005; Penma sa e al., 2013; Wang e al., 2015; Coleman e al., 2016). Ligands binding si es include he cen al binding si e (S1) and seconda y binding si e (S2) ha o e laps he ex acellula loop (EL4; Figu e 1A). Conse ed esidues in binding si es desc ibed by Koldsø e al. (2015) ha e nea ly he same o ame s excep o F317. Low-conse ed esidues in binding si es desc ibed by Ande sen e al. (2015) con ol he selec i eness o hNET and side-chain con o ma ions o hese esidues can a ec he quali y o he model (shown in Figu e 1A). As men ioned ea lie , he side-chains o iden ical aligned esidues exhibi nea ly iden ical o ame s. As many as 53 amino acid esidues in hNET ha ha e iden i y wi h hSERT and no dDAT can be used om he hSERT s uc u e o complemen he o ame s and imp o e accu acy o s uc u e (Haddad e al., 2016). We ecommend ha he cons uc ed homology model is alida ed o selec i i y by docking o p e iously known ligands such as neu o ansmi e s and inhibi o s. ALK ALK is a ecep o y osine kinase o iginally disco e ed by ch omosomal ea angemen associa ed wi h anaplas ic la ge cell lymphoma. ALK was epo ed o be cons i u i ely ac i a ed by gene ampli ica ion in se e al neu oblas oma cell lines (Osajima-Hakomo i e al., 2005), while neu oblas oma-speci ic mu a ions in ALK we e sui able a ge s o de elopmen o se e al inhibi o he apeu ics (Ba one e al., 2013). The h ee classes o ALK mu a ions include a cons i u i ely ac i e gain- o - unc ion ecep o (ligand-independen ), kinase dead mu an s, and ligand-dependen mu an s (Chand e al., 2013). Fusion p o eins in ol ing he in acellula kinase domain o ALK cause se e al ypes o cance and has been a ge ed by kinase inhibi o s. In addi ion, se e al mu a ions in ALK kinase domain esul in d ug esis ance (Roskoski, 2013). The ad an ages o homology modeling o he ex acellula domains include accessibili y on cell su ace and pe haps less c oss in e ac ion han kinase inhibi o s. ALK gene codes o a p o ein o app oxima ely 1620 esidues (Table 1). The c ys al s uc u e o he kinase domain shows he in e ac ions o selec i e d ugs wi h mu an ALK (Sakamo o e al., 2011; Eps ein e al., 2012; F on ie s in Molecula Neu oscience | www. on ie sin.o g 3Janua y 2017 | Volume 10 | A icle 7 Haddad e al. Homology Modeling o Ta ge ing Neu oblas oma FIGURE 1 | Rep esen a ions o he human no epineph ine anspo e (hNET), anaplas ic lymphoma kinase (ALK) and opomyosin ecep o kinase B (T kB) s uc u es ea u ing he mos di e gen egions which equi e p ecise alignmen and possibly loop modeling. Di e gen loops a e shown in ep esen a i e alignmen s wi h closes known homolog s uc u es. (A) hNET. Two di e gen ex acellula loops and wo in acellula loops a e shown. A op iew o hNET is shown on he le . Low-conse ed esidues in binding si es as desc ibed by Ande sen e al. (2015) a e highligh ed in colo s: cen al binding si e (S1), seconda y binding si e (S2) and ex acellula loop 4 (EL4). Red and blue ci cles highligh S1 and S2 si es, espec i ely. (B) ALK ex acellula domains. Conse ed yp ophan in he MAM domains mus be embedded in he cen e o s uc u e (i.e., W288 and W501). Since he alignmen o MAM2 ( egion o W501) was co ec ed manually, u he loop modeling o he egion is equi ed (pa icula ly o P496 and P499). Highligh ed conse ed esidues ha a e binding he calcium ion in he Low-densi y lipop o ein ecep o class A (LDLa) domain a e impo an o alignmen . (C) T kB ex acellula domains. Th ee majo domains o he T kB s uc u e can be used in analysis. The leucine ich epea (LRR) and Ig-like C2 Type 2 egions can be cons uc ed by homology modeling. Two shi s a e shown, ha migh equi e loop modeling. I is possible ha di e gen loops be ween T k p o eins migh play ole in he selec i i y and c oss-in e ac ions wi h neu o ophins. The Ig-like C2 ype 1 domain, di ec ly connec ed o he ansmemb ane domain, has been illus a ed by X- ay c ys allog aphy s udies o he h ee T ks. Fi ing o he h ee T ks showed a di e gen loop a T kB 334–341 egion; possibly playing ole in he selec i i y o hese T ks o di e en neu o ophins. F on ie s in Molecula Neu oscience | www. on ie sin.o g 4Janua y 2017 | Volume 10 | A icle 7 Haddad e al. Homology Modeling o Ta ge ing Neu oblas oma TABLE 1 | Templa es o homology modeling o human no epineph ine anspo e (hNET) and ex acellula domains o anaplas ic lymphoma kinase (ALK) and opomyosin ecep o kinase B (T kB). Ta ge (ID) Leng h Templa e (PDB IDs) Iden i y Co e age Main domains Re e ence hNET (P23975) 617 LeuT (2A65) 150/541 (28%)56−578 All Yamashi a e al. (2005) dDAT (4M48) 320/548 (58%)56−601 All Penma sa e al. (2013) dDAT (4XPA) 322/547 (59%)56−601 All Wang e al. (2015) SERT- s2 (5I6Z) 291/548 (53%)51−595 All Coleman e al. (2016) ALK (Q9UM73) 1620 PTPRM (2C9A and 2V5Y) 25/164 (15%)∗264−427 MAM1 A icescu e al. (2006, 2007) 21/159 (13%)∗481−636 MAM2 MEP1B (4GWM) 19/164 (12%)∗264−427 MAM1 A olas e al. (2012) 17/159 (11%)∗481−636 MAM2 LDLR (2KRI) 15/37 (41%)437−473 LDLa Lee e al. (2010) T kB (Q16620) 822 T kA (2IFG) 89/256 (35%)32−281 Ig-like C2 Type2, LRR Weh man e al. (2007) ∗Many iden i ies we e los due o posi ion-speci ic mul iple alignmen . Huang e al., 2014). All known c ys al models o ALK co e he amino acid ange 1058–1411 and un o una ely he ex acellula s uc u e has no been well s udied. The egion spanning he ex acellula pa o he ecep o ∼266–636 comp ises wo mep in/A5/mu domains also known as he MAM domains (Figu e 1). MAM1 spans 264–427 and MAM2 spans 478–636. App oxima ely 16 N-linked glycosyla ed si es a e eco ded spo adically in he ex acellula egion. C ys al s uc u es o he MAM domain o ecep o p o ein y osine phospha ase MU, also known as PTPRM (A icescu e al., 2006, 2007), and Mep in A be a, also known as MEP1B (A olas e al., 2012) can se e as mul iple empla es o he ex acellula domain o ALK. Al hough many sequence iden i ies a e los due o posi ional alignmen (Table 1), he dis inc MAM domains o PTPRM and MEP1B a e highly simila wi h ∼1.35 Å oo -mean- squa e de ia ion (RMSD) o Cαa oms and ∼1.43 Å RMSD o all a oms. Two loop egions in MAM1 domain equi e loop modeling (Figu e 1B). The o me loop egion con ains conse ed yp ophan (W288) e y well s acked in he cen e o he domain. The equi alen yp ophan (W501) in MAM2 was misaligned in he posi ion-speci ic alignmen and mus be co ec ed o p ope modeling (Figu e 1B). Simila o hNET, glycosyla ed esidues o he MAM domains can be used o check he o ien a ion o side chains as hey should be acing solu ion. A low-densi y lipop o ein ecep o class A (LDLa) domain spans he egion 437–473 be ween he wo MAM domains. The LDLR s uc u e (Lee e al., 2010) is he mos ela ed homolog (Table 1). A leas h ee conse ed aspa ic acid esidues and one glu amic acid coo dina e a calcium ion in he LDLa domain (Figu e 1B). T kB The neu o ophic T ks, assis ed by p75 neu o ophin ecep o , play an essen ial ole in biology o neu ons by media ing neu o ophin-ac i a ed signaling. Neu o ophins include ne e g ow h ac o (NGF), b ain-de i ed neu o ophic ac o (BDNF), neu o ophin-3 (NT-3), neu o ophin-4/5 (NT-4/5), neu o ophin-6 and neu o ophin-7 (Ul sch e al., 1999). The exp ession o ype 1 (T kA) and ype 2 (T kB) ecep o s is associa ed wi h a o able and un a o able p ima y neu oblas oma pa ien ou come, espec i ely (Thiele and Reynolds, 2005). The e a e ou p o ein iso o ms o T kA epo ed in he Unip o da abase (ID: P04629). The longes is 796 esidues in leng h. C ys al s uc u es co e wo la ge segmen s o he ex acellula ; (Robe son e al., 2001; Weh man e al., 2007), and in acellula T kA p o ein (Wang e al., 2012). On he o he hand, ou o se en al e na i e iso o ms, he canonical iso o m o T kB is 822 esidues in leng h (Table 1). The c ys al s uc u es o T kB co e he in acellula kinase domain (Be and e al., 2012) and Ig-like C2 Type 1 domain o he ex acellula egion (PDB IDs: 1WWB, 1HCF; Ul sch e al., 1999; Ban ield e al., 2001). The es o ex acellula segmen o T kB ( esidues 32–281) can be econs uc ed by homology modeling o T kA empla e which has ∼35% iden i y (Table 1). The empla e allows o modeling o wo majo ex acellula domains o T kB; namely, he leucine ich epea (LRR) spanning egion 92–137, and he Ig-like C2 Type 2 domain spanning he esidues 197–281 (Figu e 1C). A leas wo alignmen shi s in he LRR and Ig-like C2 ype 2 domains equi e loop modeling. By supe posing he h ee known s uc u es o Ig-like C2 ype 1 domains o T kA, T kB and T kC (PDB IDs: 1WWA, 1WWB, and 1WWC, espec i ely), a di e gen loop spanning T kB 334–341 egion is highligh ed (Figu e 1C). Along wi h his loop, se e al di e gen esidues migh also play ole in he selec i i y o hese T ks o di e en neu o ophins. Howe e , u he wo k is equi ed o iden i y he exac binding si es o di e en neu o ophins (Ul sch e al., 1999). In ac , he ne wo k o T k-neu o ophin is mo e complex i we assume ha ei he Ig-like C2 Type 2 and LRR domains would be in ol ed in neu o ophins in e ac ions. In ensi e wo k in homology modeling, molecula docking and molecula dynamics is equi ed o shed he ligh on his ne wo k. Simila o he si ua ion in hNET and ALK, inhibi o s a ge ing se e al T k ecep o s a he same ime esul in a ge ing o se e al pa hways and lead o se e al d ug side e ec s. Unde s anding he selec i i y o T ks ecep o s will play signi ican ole in de elopmen o he apeu ics. CONCLUSIONS AND PERSPECTIVES Homology modeling is one o he i s s eps in de eloping he apeu ics o new a ge s. Howe e , as we showed he e he i s s eps a e o en c ucial and de imen al in cons uc ing F on ie s in Molecula Neu oscience | www. on ie sin.o g 5Janua y 2017 | Volume 10 | A icle 7 Haddad e al. Homology Modeling o Ta ge ing Neu oblas oma new homology s uc u es, no o men ion in de eloping new d ugs. Al hough he ules o ‘‘good modeling p ac ice’’ a e no w i en ye , many lessons can be lea ned by e alua ion o he model and co ec ing/a oiding e o s a ea ly s ages o modeling. On he o he hand, a bad quali y empla e will no gi e a good quali y homology model. The quali y and iden i y o he empla e(s) a e e y impo an issues. Low-conse ed egions in he p o ein a ge o en play a signi ican biological ole. They equi e mo e ocus in homology modeling and in a design o new he apeu ics. Se e al s a egies o neu oblas oma he apy ha e been ad ancing in pa allel in he pas ew decades. Ta ge ing he cell su ace molecules is a s a egy ha allows o dis ibu ion o e o s. The dis ibu ion o e o s is de ined by e ec i e esea ch managemen whe e asks a e dis ibu ed among esea che s o p oduce mo e e icien he apeu ics. Indeed, no el cance he apeu ics comp ise complexes o se e al agen s ha ca y ou se e al unc ions. The selec i e a ge ing agen (e.g., pep ide o an ibody) deli e s he ca go (i.e., oxic agen ) o he cance cell, which also equi es a ca ie (soluble/ eleasing agen ) o a memb ane pene a ing agen . In his pe spec i e a icle, he modele has a mo e ocused objec i e, which is o de elop a ‘‘selec i e’’ a ge ing molecule. We hope ha hese s a egies will p oduce mo e adap able, e icien and pe sonalized he apeu ics in he u u e. AUTHOR CONTRIBUTIONS All au ho s con ibu ed o he design o wo k. YH w o e he manusc ip . ZH e iewed he manusc ip , and VA was p inciple in es iga o and con ibu o o scheme and o ganiza ion o wo k. FUNDING We g a e ully acknowledge he Czech Agency o Heal hca e Resea ch, AZV (15-28334A) and Minis y o Educa ion, You h and Spo s o he Czech Republic unde he p ojec CEITEC 2020 (LQ1601) o inancial suppo o his wo k. The compu a ional esou ces we e p o ided by he CESNET LM2015042 and he CERIT Scien i ic Cloud LM2015085, p o ided unde he p og amme ‘‘P ojec s o La ge Resea ch, De elopmen and Inno a ions In as uc u es’’. REFERENCES Al-Lazikani, B., Jung, J., Xiang, Z. X., and Honig, B. (2001). P o ein s uc u e p edic ion. Cu . Opin. Chem. Biol. 5, 51–56. doi: 10.1016/S1367- 5931(00)00164-2 Ande sen, J., Rings ed, K. B., Bang-Ande sen, B., S ømgaa d, K., and K is ensen, A. S. (2015). Binding si e esidues con ol inhibi o selec i i y in he human no epineph ine anspo e bu no in he human dopamine anspo e . Sci. Rep. 5:15650. doi: 10.1038/s ep15650 A icescu, A. R., Hon, W. C., Siebold, C., Lu, W., an de Me we, P. A., and Jones, E. Y. (2006). Molecula analysis o ecep o p o ein y osine phospha ase µ-media ed cell adhesion. EMBO J. 25, 701–712. doi: 10.1038/sj.emboj. 7600974 A icescu, A. R., Siebold, C., Choudhu i, K., Chang, V. T., Lu, W., Da is, S. J., e al. (2007). S uc u e o a y osine phospha ase adhesi e in e ac ion e eals a space -clamp mechanism. Science 317, 1217–1220. doi: 10.1126/science. 1144646 A olas, J. L., B ode , C., Je e son, T., Gue a a, T., S e chi, E. E., Bode, W., e al. (2012). S uc u al basis o he sheddase unc ion o human mep in β me allop o einase a he plasma memb ane. P oc. Na l. Acad. Sci. U S A 109, 16131–16136. doi: 10.1073/pnas.1211076109 Ban ield, M. J., Naylo , R. L., Robe son, A. G. S., Allen, S. J., Dawba n, D., and B ady, R. L. (2001). Speci ici y in T k ecep o : neu o ophin in e ac ions: he c ys al s uc u e o T kB-d5 in complex wi h neu o ophin-4/5. S uc u e 9, 1191–1199. doi: 10.1016/S0969-2126(01)00681-5 Ba one, G., Ande son, J., Pea son, A. D. J., Pe ie, K., and Chesle , L. (2013). New s a egies in neu oblas oma: he apeu ic a ge ing o MYCN and ALK. Clin. Cance Res. 19, 5814–5821. doi: 10.1158/1078-0432.cc -13-0680 Be and, T., Ko he, M., Liu, J., Dupuy, A., Rak, A., Be ne, P. F., e al. (2012). The c ys al s uc u es o T kA and T kB sugges key egions o achie ing selec i e inhibi ion. J. Mol. Biol. 423, 439–453. doi: 10.1016/j.jmb.2012.08.002 Bo dne , A. J. (2012). Fo ce ields o homology modeling. Me hods Mol. Biol. 857, 83–106. doi: 10.1007/978-1-61779-588-6_4 Bo doli, L., Kie e , F., A nold, K., Benke , P., Ba ey, J., and Schwede, T. (2009). P o ein s uc u e homology modeling using SWISS-MODEL wo kspace. Na . P o oc. 4, 1–13. doi: 10.1038/np o .2008.197 B odeu , G. M., P i cha d, J., Be hold, F., Ca lsen, N. L. T., Cas el, V., Cas lebe y, R. P., e al. (1993). Re isions o he in e na ional c i e ia o neu oblas oma diagnosis, s aging and esponse o ea men . J. Clin. Oncol. 11, 1466–1477. Bu le , K. V., Kalin, J., B ochie , C., Vis oli, G., Langley, B., and Kozikowski, A. P. (2010). Ra ional design and simple chemis y yield a supe io , neu op o ec i e HDAC6 inhibi o , Tubas a in A. J. Am. Chem. Soc. 132, 10842–10846. doi: 10.1021/ja102758 Chand, D., Yamazaki, Y., Ruu h, K., Schönhe , C., Ma insson, T., Kogne , P., e al. (2013). Cell cul u e and D osophila model sys ems de ine h ee classes o anaplas ic lymphoma kinase mu a ions in neu oblas oma. Dis. Model. Mech. 6, 373–382. doi: 10.1242/dmm.010348 Chen, V. B., A endall, W. B., Headd, J. J., Keedy, D. A., Immo mino, R. M., Kap al, G. J., e al. (2010). MolP obi y: all-a om s uc u e alida ion o mac omolecula c ys allog aphy. Ac a C ys allog . D Biol. C ys allog . 66, 12–21. doi: 10.1107/S0907444909042073 Coleman, J. A., G een, E. M., and Gouaux, E. (2016). X- ay s uc u es and mechanism o he human se o onin anspo e . Na u e 532, 334–339. doi: 10.1038/na u e17629 DeVo e, N. M., and Sco , E. E. (2012). S uc u es o cy och ome P450 17A1 wi h p os a e cance d ugs abi a e one and TOK-001. Na u e 482, 116–119. doi: 10.1038/na u e10743 Eps ein, L. F., Chen, H., Emkey, R., and Whi ing on, D. A. (2012). The R1275Q neu oblas oma mu an and ce ain ATP-compe i i e inhibi o s s abilize al e na i e ac i a ion loop con o ma ions o anaplas ic lymphoma kinase. J. Biol. Chem. 287, 37447–37457. doi: 10.1074/jbc.M112. 391425 Ga cia, J., Faca, V., Ja zembowski, J., Zhang, Q., Pa k, J., and Hanash, S. (2009). Comp ehensi e p o iling o he cell su ace p o eome o Sy5Y neu oblas oma cells yields a subse o p o eins associa ed wi h umo di e en ia ion. J. P o eome Res. 8, 3791–3796. doi: 10.1021/p 800964 Haddad, Y., Hege , Z., and Adam, V. (2016). Guidelines o homology modeling o dopamine, no epineph ine and se o onin anspo e s. ACS Chem. Neu osci. 7, 1607–1613. doi: 10.1021/acschemneu o.6b00242 Huang, Q., Johnson, T. W., Bailey, S., B ooun, A., Bunke , K. D., Bu ke, B. J., e al. (2014). Design o po en and selec i e inhibi o s o o e come clinical anaplas ic lymphoma kinase mu a ions esis an o c izo inib. J. Med. Chem. 57, 1170–1187. doi: 10.1021/jm401805h Kakuda, S., Shiba, T., Ishigu o, M., Tagawa, H., Oka, S., Kajiha a, Y., e al. (2004). S uc u al basis o accep o subs a e ecogni ion o a human glucu onyl ans e ase, GlcAT-P, an enzyme c i ical in he biosyn hesis o he ca bohyd a e epi ope HNK-1. J. Biol. Chem. 279, 22693–22703. doi: 10.1074/jbc.M400622200 F on ie s in Molecula Neu oscience | www. on ie sin.o g 6Janua y 2017 | Volume 10 | A icle 7 Haddad e al. Homology Modeling o Ta ge ing Neu oblas oma Kinch, M. S., Hoye , D., Pa idge, E., and Plumme , M. (2015). Ta ge selec ion o FDA-app o ed medicines. D ug Disco . Today 20, 784–789. doi: 10.1016/j. d udis.2014.11.001 Koldsø, H., Ch is iansen, A. B., Sinning, S., and Schiø , B. (2013). Compa a i e modeling o he human monoamine anspo e s: simila i ies in subs a e binding. ACS Chem. Neu osci. 4, 295–309. doi: 10.1021/cn300148 Koldsø, H., G oule , J., and Schiø , B. (2015). Insigh s o ligand binding o he monoamine anspo e s- om homology modeling o LeuBAT and dDAT. F on . Pha macol. 6:208. doi: 10.3389/ pha .2015.00208 K iege , E., Nabuu s, S. B., and V iend, G. (2003). Homology modeling. Me hods Biochem. Anal. 44, 509–523. doi: 10.1007/sp inge e e ence_33987 Kund o as, P. J., Zhu, Z., Janin, J., and Vakse , I. A. (2012). Templa es a e a ailable o model nea ly all complexes o s uc u ally cha ac e ized p o eins. P oc. Na l. Acad. Sci. U S A 109, 9438–9441. doi: 10.1073/pnas.1200678109 Lee, C. J., De Biasio, A., and Beglo a, N. (2010). Mode o in e ac ion be ween be a 2GPI and lipop o ein ecep o s sugges s mu ually exclusi e binding o be a 2GPI o he ecep o s and anionic phospholipids. S uc u e 18, 366–376. doi: 10.1016/j.s .2009.12.013 Ma hay, K. K., Geo ge, R. E., and Yu, A. L. (2012). P omising he apeu ic a ge s in neu oblas oma. Clin. Cance Res. 18, 2740–2753. doi: 10.1158/1078-0432.CCR- 11-1939 Melikian, H. E., McDonald, J. K., Gu, H., Rudnick, G., Moo e, K. R., and Blakely, R. D. (1994). Human no epineph ine anspo e –biosyn he ic-s udies using a si e-di ec ed polyclonal an ibody. J. Biol. Chem. 269, 12290–12297. Mo ensen, O. V., and Ko age e, S. (2015). Designing modula o s o monoamine anspo e s using i ual sc eening echniques. F on . Pha macol. 6:223. doi: 10.3389/ pha .2015.00223 No egaa d, L., F ede iksen, D., Nielsen, E. O., and Ge he , U. (1998). Delinea ion o an endogenous zinc-binding si e in he human dopamine anspo e . EMBO J. 17, 4266–4273. doi: 10.1093/emboj/17.15.4266 Osajima-Hakomo i, Y., Miyake, I., Ohi a, M., Nakagawa a, A., Nakagawa, A., and Sakai, R. (2005). Biological ole o anaplas ic lymphoma kinase in neu oblas oma. Am. J. Pa hol. 167, 213–222. doi: 10.1016/s0002- 9440(10)62966-5 Penma sa, A., Wang, K. H., and Gouaux, E. (2013). X- ay s uc u e o dopamine anspo e elucida es an idep essan mechanism. Na u e 503, 85–90. doi: 10.1038/na u e12533 Robe son, A. G. S., Ban ield, M. J., Allen, S. J., Dando, J. A., Mason, G. G. F., Tyle , S. J., e al. (2001). Iden i ica ion and s uc u e o he ne e g ow h ac o binding si e on T kA. Biochem. Biophys. Res. Comm. 282, 131–141. doi: 10.1006/bb c.2001.4462 Roskoski, R. J . (2013). The p eclinical p o ile o c izo inib o he ea men o non-small-cell lung cance and o he neoplas ic diso de s. Expe Opin. D ug Disco . 8, 1165–1179. doi: 10.1517/17460441.2013.813015 Sakamo o, H., Tsukaguchi, T., Hi oshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., e al. (2011). CH5424802, a selec i e ALK inhibi o capable o blocking he esis an ga ekeepe mu an . Cance Cell 19, 679–690. doi: 10.1016/j.cc .2011.04.004 Sa ele , H., Imb iglio, T., Nyalendo, C., Haddad, E., Annabi, B., Du al, M., e al. (2012). CD133 exp ession is associa ed wi h poo ou come in neu oblas oma ia chemo esis ance media ed by he AKT pa hway. His opa hology 60, 1144–1155. doi: 10.1111/j.1365-2559.2012.04191.x Schlessinge , A., Geie , E., Fan, H., I win, J. J., Shoiche , B. K., Giacomini, K. M., e al. (2011). S uc u e-based disco e y o p esc ip ion d ugs ha in e ac wi h he no epineph ine anspo e , NET. P oc. Na l. Acad. Sci. U S A 108, 15810–15815. doi: 10.1073/pnas.1106030108 Schli e , A. M., Do nebu g, C., Ba h, T. F. E., Wahl, J., Schul e, J. H., B üde lein, S., e al. (2012). CD57 high neu oblas oma cells ha e agg essi e a ibu es ex si u and an undi e en ia ed pheno ype in pa ien s. PLoS One 7:e42025. doi: 10.1371/jou nal.pone.0042025 Sco , A. M., Wolchok, J. D., and Old, L. J. (2012). An ibody he apy o cance . Na . Re . Cance 12, 278–287. doi: 10.1038/n c3236 Shin, M. C., Zhang, J., Min, K. A., Lee, K., Byun, Y., Da id, A. E., e al. (2014). Cell-pene a ing pep ides: achie emen s and challenges in applica ion o cance ea men . J. Biomed. Ma e . Res. A 102, 575–587. doi: 10.1002/jbm.a. 34859 Siegel, R. L., Mille , K. D., and Jemal, A. (2016). Cance s a is ics, 2016. CA Cance J. Clin. 66, 7–30. doi: 10.3322/caac.21332 Thiele, C. J., and Reynolds, C. P. (2005). ‘‘Di e en ia ion and e inoids,’’ in Neu oblas oma, eds N. K. V. Cheung and S. L. Cohn (New Yo k, NY: Sp inge ), 243–256. To o , M. (2012). Loop simula ions. Me hods Mol. Biol. 587, 207–229. doi: 10.1007/978-1-61779-588-6_9 Ul sch, M. H., Wiesmann, C., Simmons, L. C., Hen ich, J., Yang, M., Reilly, D., e al. (1999). C ys al s uc u es o he neu o ophin-binding domain o T kA, T kB and T kC. J. Mol. Biol. 290, 149–159. doi: 10.1006/jmbi.1999.2816 Ve issimo, C. S., Molenaa , J. J., Fi zsimons, C. P., and V eugdenhil, E. (2011). Neu oblas oma he apy: Wha is in he pipeline? Endoc . Rela . Cance 18, R213–R231. doi: 10.1530/ERC-11-0251 Wang, T., Lamb, M. L., Block, M. H., Da ies, A. M., Han, Y., Ho mann, E., e al. (2012). Disco e y o disubs i u ed imidazo [4,5-b] py idines and pu ines as po en T kA inhibi o s. ACS Med. Chem. Le . 3, 705–709. doi: 10.1021/ml300074j Wang, K. H., Penma sa, A., and Gouaux, E. (2015). Neu o ansmi e and psychos imulan ecogni ion by he dopamine anspo e . Na u e 521, 322–327. doi: 10.1038/na u e14431 Webb, B., and Sali, A. (2014). Compa a i e p o ein s uc u e modeling using modelle . Cu . P o oc. Bioin o ma ics 47, 5.6.1–5.6.32. doi: 10. 1002/0471250953.bi0506s47 Weh man, T., He, X., Raab, B., Dukipa i, A., Blau, H., and Ga cia, K. C. (2007). S uc u al and mechanis ic insigh s in o ne e g ow h ac o in e ac ions wi h he T kA and p75 ecep o s. Neu on 53, 25–38. doi: 10.1016/j.neu on.2006. 09.034 W igh , K. E., Hje ild, K. A., Ba le , J., Douglas, A. D., Jin, J., B own, R. E., e al. (2014). S uc u e o mala ia in asion p o ein RH5 wi h e y h ocy e basigin and blocking an ibodies. Na u e 515, 427–430. doi: 10.1038/na u e 13715 Yamashi a, A., Singh, S. K., Kawa e, T., Jin, Y., and Gouaux, E. (2005). C ys al s uc u e o a bac e ial homologue o Na+/Cl–dependen neu o ansmi e anspo e s. Na u e 437, 215–223. doi: 10.1038/na u e 03978 Con lic o In e es S a emen : The au ho s decla e ha he esea ch was conduc ed in he absence o any comme cial o inancial ela ionships ha could be cons ued as a po en ial con lic o in e es . Copy igh © 2017 Haddad, Hege and Adam. This is an open-access a icle dis ibu ed unde he e ms o he C ea i e Commons A ibu ion License (CC BY). The use, dis ibu ion and ep oduc ion in o he o ums is pe mi ed, p o ided he o iginal au ho (s) o licenso a e c edi ed and ha he o iginal publica ion in his jou nal is ci ed, in acco dance wi h accep ed academic p ac ice. No use, dis ibu ion o ep oduc ion is pe mi ed which does no comply wi h hese e ms. F on ie s in Molecula Neu oscience | www. on ie sin.o g 7Janua y 2017 | Volume 10 | A icle 7